---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-207633"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:51:47.521809+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha Q1 net loss $42.4M; FDA aligns on TSHA-102 BLA submission pathway

## Summary
- Net loss $42.4M ($0.12/sh) vs $21.5M ($0.08/sh) Q1 2025; R&D expense doubled to $33.8M on PPQ and clinical costs.
- Cash $276.6M; company expects runway into 2028.
- FDA reaffirmed alignment on TSHA-102 BLA pathway including pivotal trial design, endpoints, and potential 6-month interim submission.
- Dosing in REVEAL pivotal and ASPIRE trials on track for Q2 2026 completion; no treatment-related SAEs or DLTs to date.
- BLA-enabling PPQ campaign initiated April 2026; completion expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-207633
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/0001193125-26-207633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-207633
- JSON: https://secwatch.observer/filing/0001193125-26-207633.json
- Plain text: https://secwatch.observer/filing/0001193125-26-207633.txt

## Source-grounded claims
- claim_id: 6452773e2b2ac9283dc6f4ee8fbb9ed28096e604
  claim: Taysha Gene Therapies, Inc. reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: On May 6, 2026, Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2026, and recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/0001193125-26-207633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.